ScholarLens Back to search
2020•Cochrane Clinical AnswersRequires access

What is the effect of adding a disease-modifying antirheumatic drug (DMARD) to methotrexate (MTX) for people with rheumatoid arthritis and an inadequate response to MTX alone?

Jane Burch, Jaimo Ahn

Open publisher page 0 citations

Abstract

This record does not include an abstract. Use the full-text link above if available.

About this research paper

What this paper is about

An abstract is not available in the OpenAlex record for this paper.

Why it matters

A significance statement is not available in the OpenAlex record.

Key contribution

A contribution statement is not available in the OpenAlex record.

Method / approach

Method details are not available in the OpenAlex metadata.

Main findings

Findings are not separately available in the OpenAlex metadata.

Limitations

Limitations are not available in the OpenAlex metadata.

Applications

Application details are not available in the OpenAlex metadata.

Key concepts: Rheumatoid arthritis, Methotrexate, Antirheumatic drugs, Medicine, Antirheumatic Agents, Drug, Internal medicine, Pharmacology

Related papers

Related paper 1Related paper 2
Back to paper searchBrowse research topicsOriginal source
What is the effect of adding a disease-modifying antirheumatic drug (DMARD) to methotrexate (MTX) for people with rheumatoid arthritis and an inadequate response to MTX alone? — Research Paper | ScholarLens